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Abstract 
Croralus adamanteus snake venom adamalysin I1 is the structural prototype of the adamalysin or ADAM family 
comprising proteolytic domains of snake venom metatloproteinases, multimodular mammalian reproductive tract pro- 
teins, and tumor necrosis factor a convertase, TACE, involved in the release of the inflammatory cytokine, TNFa. The 
structure of adamalysin I1 in noncovalent complex with two small-molecule right-hand side peptidomimetic inhibitors 
(Pol  647 and Pol 656) has been solved using X-ray diffraction data up to 2.6 and 2.8 8, resolution. The inhibitors bind 
to the S’-side of the proteinase, inserting between two protein segments, establishing a mixed parallel-antiparallel 
three-stranded P-shest and coordinate the central zinc ion in a bidentate manner via their two C-terminal oxygen atoms. 
The proteinase-inhibitor complexes are described in detail and are compared with other known structures. An adamalysin- 
based model of the active site of TACE reveals that these small molecules would probably fit into the active site cleft 
of this  latter metalloproteinase, providing a starting model for the rational design of  TACE inhibitors. 
Keywords: ADAM; adamalysin; snake venom prokinase; X-ray structure; zine endopeptidase 
Adamalysin I1 (E.C. 3.4.24.46) is a 203-amino acid metalloendo- 
peptidase (MEP) isolated from the venom of the Eastern diamond- 
back rattlesnake Crotalus adamanteus (Kurecki et al., 1978; Kress 
& Catanese, 1981). It has been shown to exhibit no significant 
hemorrhagic activity at the envenomation site upon snake bite, but 
to readily inactivate serpins by limited proteolysis of their reactive 
site loops (Kurecki et al., 1978; Kress, 1986). Adamalysin I1 is a 
single-chain 24-kDa protein requiring zinc and calcium for its 
activity. It displays a close sequential similarity to the low molec- 
ular weight Croralus atrox MEPs Ht-c and Ht-d, which are capable 
of degrading type IV collagen and various gelatins, and are  con- 
sidered as locally (at the envenomation site) or systemically hem- 
orrhagic (affecting heart, lungs, kidneys, and brain; Shannon et al., 
1989; Hite et al., 1994). Adamalysin I1 displays proteolytic activity 
only toward longer (penta-, hexa-) peptides, i.e., requires an ex- 
tended substrate binding site interaction (Kurecki et al., 1978; 
Kress & Catanese, 1981), and prefers medium-sized hydrophobic 
residues at Pi and Pi (Schechter & Berger, 1967). 
Reprint requests to: EX. Gomis-Ruth, Department de Biologia Molec- 
ular i Cel.lular, Centre d’hvestigacib i Desenvolupament C.S.I.C., Jordi 
Girona, 18-26, 08034 Barcelona, Spain; e-mail: xgrcri@cid.csic.es. 
This enzyme is the structural prototype of the adamalysin- 
family of zinc-dependent endopeptidases (Stocker et al., 1995), 
which have also been called reprolysins or ADAMS (Bjamason & 
Fox, 1994; Wolfsberg et al., 1995a, 1995b). Together with the serra- 
lysins, astacins, vertebrate collagenases/matrix metalloproteinases/ 
matrixins (MMPs), leishmanolysin (Schlagenhauf et al., 1995), and 
a zinc endoprotease from Streptomyces caespitosus (Kurisu et al., 
1997), the adamalysins are grouped together in the metzincin clan 
of AEPs (Bode et al., 1993; Stocker et al.,  1995). Like the other metz- 
incins, the adamalysins  comprise an elongated zinc binding con- 
sensus  sequence  HEXXHXXGXXH  and a so-called  “Met-turn” 
forming the hydrophobic base of the catalytic zinc-binding site. The 
three histidine residues of the consensus sequence are involved in 
zinc ligation, and the glutamic acid residue presumably is  the gen- 
eral base in catalysis (Matthews, 1988; Bode et al., 1993; Stocker 
et al., 1995). 
Adamalysins include hemorrhagic and nonhemorrhagic protein- 
ases from snake venoms (Hite et al., 1992, 1994; Kini & Evans, 
1992), mammalian reproductive tract and cell-fusion proteins 
(Wolfsberg et al., 1995b; Huovila et al., 1996), proteins involved 
in embryonic development (Alfandari et al., 1997), and a tumor 
suppressor gene product (Emi et al., 1993). Recently, three new 
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proteinases isolated from bovine and porcine spleen and human 
monocytes (Black et al., 1997; Lunn et al., 1997; Moss et al., 
1997) with the ability to release soluble tumor necrosis factor-a 
(TNFa), an important inflammatory cytokine, from its membrane- 
bound precursor by limited proteolysis of bond Ala 76-Val 77 have 
been described at the primary structure level. These TNFa-con- 
verting enzymes, TACE, have been putatively proposed to be mem- 
bers of the adamalysin family. This task has been shown to be 
performed also by members of the MMP family, whereas MMP 
inhibitors block the release of active TNFa in vitro and the devel- 
opment of acute lipopolysaccharide (endotoxin) shock in vivo (Gear- 
ing et al., 1994; McGeehan et al., 1994; Mohler et al., 1994). 
Recently, two hemorrhagic snake-venom adamalysins, isolated from 
Bothrops juraracu and Echis curinatus luekeyi venoms, have been 
shown to be able to release active TNFa at the envenomation site, 
establishing an in vivo correlation between cytokine release and 
local inflammation and venom-induced necrosis upon snake bite, 
because the envenomation events are partially reduced by the ad- 
ministration of ovine TNFa Fab antibodies (Moura  da Silva et al., 
1996). 
Adamalysins are mostly multidomainal proteins with an ap- 
proximately 24-kDa central catalytic zinc-containing proteinase 
domain flanked by an activation peptide, and followed by a dis- 
integrin-like domain and a cystein-rich domain (Neeper & Jacob- 
son, 1990; Hite et al., 1992, 1994; Kini & Evans, 1992). Additional 
modules, such  as EGF-like, crambin-like, transmembrane, and cy- 
toplasmic domains, have been described (Wolfsberg et al., 1995b; 
Black et  al.,  1997; Moss et al., 1997). In these larger multidomain 
enzymes, activation is believed to occur as in MMPs, i.e., follow- 
ing a cysteine-switch mechanism (Springman et al., 1990; Hite 
et al., 1992; Grams et al., 1993). A cysteine residue in a strictly 
conserved PKMCGV region, approximately 20 residues N-terminal 
from the start of the mature protein sequence, is believed to block 
the catalytic zinc in the proenzyme, preventing substrate accessi- 
bility of the active site cleft. Upon proteolytic activation cleavage, 
the peptide and, thus, the sulfur-zinc ligand, are removed, the 
latter being replaced in the active enzyme by a solvent molecule. 
Protein inhibitors directed against adamalysins have been found 
in the blood sera of some mammals and snakes, the most note- 
worthy being the American marsupial opossum (Didelphis virgini- 
una) and the Habu snake (Catanese & Kress, 1992; Yamakawa & 
Omori-Satoh,  1992). Some synthetic  peptides, with cysteine- 
switch consensus sequences, of mammalian vertebrate collagenses 
and snake venoms were shown to inhibit snake venom a-proteinase 
(Nomura & Suzuki, 1993). Pyroglutamate (PyroG1u)-containing 
tripeptides, such as isolated from C. utrox venom, have been shown 
to inhibit MEPs, with K ,  values in the lower micromolar range: two 
tripeptides (PyroGlu-Asn-Trp and PyroGlu-Gln-Trp) are usually 
found in very high concentrations M and higher) in venom 
samples also containing MEPs, suggesting that this is the peculiar 
manner of inhibition selected by snakes in order to avoid autolysis 
before envenomation or  TNFa release (Robeva  et al., 1991). These 
peptides were originally reported to be inhibitors of kininases 
responsible for the hydrolysis of bradykinin, and also of angiotensin- 
converting enzyme, both factors that could contribute to venom- 
induced hypotensive shock (Ferreira, 1965; Cheung & Chrisman, 
1973; Bjarnason & Fox, 1994). 
We have solved the crystal and molecular structure of un- 
liganded adamalysin I1 (Gomis-Ruth et al., 1993, 1994) and have 
been able to rationalize most of its molecular properties in terms of 
its structure. Furthermore, the structure of two members of this 
MEP family, C. atrox atrolysin C (Zhang et al., 1994) and Hz- 
proteinase from Trimeresurus flavoviridis, have been published 
(Kumasaka et al., 1996). In order to study the functional determi- 
nants of inhibition of peptidomimetic inhibitors in complex with 
adamalysins, we analyzed the interactions of atrolysin C (Ht-d) 
with its natural inhibitor, PyroGlu-Asn-Trp, and with the synthetic 
compound, SCH47890  (Zhang  et al., 1994). With this publication, 
we intend to continue these investigations in a systematic manner 
and extend it to adamalysin 11, which exhibits a higher affinity to 
most of these inhibitors and represents a working model for TACE, 
in absence of a crystallographic structure of this enzyme. We show 
and analyze the crystal structures of adamalysin I1 in complex with 
two inhibitors, compare their interactions with the substrate-like 
and propeptide-like binding in MMPs, and discuss the interaction 
of S’-right-hand side inhibitors with the various subsites of the 
enzyme moiety. Furthermore, we discuss a TACE active site model 
based on the adamalysin I1 structure in light of the presently de- 
scribed enzyme-inhibitor complexes. These crystal structures are 
appropriate starting models for the development of new types of 
inhibitors by rational drug design. 
Results  and  discussion 
Figure 1 displays the chemical formulae of the two inhibitors 
investigated in complex with adamalysin I1 along with the residue 
notation used. Their ICso values for adamalysin I1 have been de- 
termined to be l .  (Pol  647) and l + M (Pol 656). Both 
inhibitors are closely related to and reminiscent of the naturally 
found endogenous venom tripeptide inhibitor PyroGlu-Asn-Trp 
present in venoms at millimolar concentrations (Robeva et al., 
1991). In Pol 647, the first residue (PyroGlu) is replaced by a 
furoyl group and, in Pol 656, additionally, the indole moiety of the 
tryptophan residue is crosslinked with the  amide nitrogen through 
a methylene group, rendering a more rigid three-membered ring 
system. This modification results in a decrease of the ICso value by 
one order of magnitude, i.e., a tighter binding to the active site of 
the enzyme moiety. 
I 
Residue FleIl I Residue TrplCtrl2 
I 
C 
Furoyl-LeusycloTrp (Po1656) 
Fig. 1. Chemical formulae and residue notation for Pol 647 and Pol 656. 
The inhibitor molecules consist of two residues, Fle and Trp/Ctr, united by 
a peptide bond. Proper topology and parameter files have been set up and 
used during refinement with X-PLOR. 
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Main features of the adamalysin II catalytic  domain 
The protein structure in the  two analyzed enzyme-inhibitor com- 
plexes is virtually identical to the native nonliganded structure 
(Gomis-Ruth et al., 1993, 1994); the RMS deviations (RMSDs) 
between the backbone atoms of adamalysin/Pol  647 and adama- 
lysin/Pol  656, respectively, and the native structure are 0.27 and 
0.25 A, Le., within the limits of coordinate errors. Only two loops 
involved in  inhibitor binding deviate to a significantly higher de- 
gree (see below). The enzyme moiety reveals an ellipsoidal shape 
with a shallow active  site  cleft separating the relatively irregularly 
folded “lower” subdomain from the more regularly organized main 
molecular body (see Fig. 2A). The “upper” domain mainly consists 
of a five-stranded P-pleated sheet of mixed parallel-antiparallel 
topology and four a-helices, and binds one calcium ion and one 
(surface  located)  sulfate anion. In this larger domain, the polypep- 
tide chain terminates in the “active-site helix” that provides the 
first two histidine residues (His 142  and His 146) embedded in the 
zinc-binding consensus sequence HEXXHXXGXXH involved in 
zinc ligation. At Gly 149, the conserved glycine residue of the 
latter sequence, the main chain turns away from the helix axis 
entering the “lower” subdomain and providing the third zinc- 
liganding histidine, His 152. In the nonliganded structure, the fourth 
metal coordination position is occupied by a solvent molecule fur- 
ther anchored to the  catalytic Glu 143 of the consensus sequence. 
Important substrate and inhibitor binding elements are the “edge” 
strand Gly 109-Asn 114 of the P-sheet  and the following “bulged” 
segment around His 129-Leu 135, which protrudes from the upper 
domain. Together they form the “upper rim” of the active site cleft 
and border both the nonprimed and primed subsites. 
The small lower domain includes a C-terminal helix (residues 
Ser 179-Lys 194) and a short disulfide-closed P-hairpin loop 
(Cys 157-Cys 1 6 4 ) ,  which precedes tight 1,4-turn (“Met-turn”), 
providing a hydrophobic base surface for the three zinc-liganding 
histidine residues. The following segment (Pro 168-Leu 170) sep- 
arates a groove representing the Si pocket from the bulk solvent 
and therefore may be called the “Si-wall forming segment.” 
Inhibitor binding 
Both inhibitors Pol 647 and Pol 656 insert between the “bulged” 
segment and the Si-wall forming segment under formation of a 
mixed parallel-antiparallel three-stranded P-sheet. Both are un- 
equivocally defined by proper electron density (see Fig. 2B,C). 
The inhibitors form two  inter main-chain hydrogen bonds with the 
“upper rim” segment (FleIl N-Lys 1 0 6  0 and FleIl  0-Ile  108 N, 
for nomenclature of the inhibitor residues, see Fig. 1) and two 
more with Leu 170 of the Si-wall forming segment via the furoyl 
group of FleIl (see Figs. 2B,C, 3). The leucyl side chain of FleIl 
points  out of the molecular body and  is  in van der Waals contact 
with the  side chain of Ile  107 (approximately 4 A). The following 
tryptophan side chain of Pol 647 (cycloTRP in Pol 656;  see Fig. l),  
constituting residue I2 (TrpI2 in Pol 647, CtrI2 in Pol 656, see 
Fig. l),  occupies the deep hydrophobic Si-pocket of adamalysin II 
without filling it completely. In fact, larger side chains with a 
further attached (aromatic) ring could be easily accommodated 
(Botos  et al., 1996). The C-terminal carboxylate  group  is coordi- 
nating the catalytic  zinc  ion in a bidentate manner (see Figs. 2B,C, 
3). One of the carboxylate oxygen atoms  is further located close to 
both oxygen atoms of the side chain of the probably protonated 
Glu 143. This latter residue is supposed to play the role of the 
general base in  the commonly accepted mechanism by means of 
which zinc proteases cleave their protein substrates (Kester & 
Matthews, 1977; Matthews, 1988; Grams et al., 1996). 
The catalytic zinc ion is liganded by the closer oxygen atom 
(Trp/CtrI2 0 1 )  of the C terminus of the inhibitor and the three Ne2 
atoms of the liganding histidine residues. The second inhibitor 
carboxylate oxygen atom (Trp/CtrI2 0 2 )  is located close to the 
surface created by His 142 Ne2, His 146 Ne2, and I2 01 ,  alto- 
gether providing a distorted pentahedral zinc ion coordination. The 
oxygen-zinc and nitrogen-zinc distances lie between 1.8 and 
2.9 8, (see Table 1). This inhibitor binding provokes a slight open- 
ing of the active site cleft. “Upper rim” atoms Gly 105 C a  and 
Lys 106 C a  are moved away 1.2 8, (0.8 in adamalysin/Pol 647) 
and 1.1 A (0.9 in adamalysin/Pol 647) from the positions in the 
noninhibited enzyme and $-wall atoms Gly 169 C a  and Pro 168 
C a  are 0.5 and 0.5 8, away, respectively (both 0.3 8, in adamalysin/ 
Pol 647). 
Comparison with the complex of Ht-d and PyroGlu-Asn-Trp 
The overall binding manner of Pol 647 and Pol 656 to adamalysin 
II is similar to that observed in the complex formed by C. atrox 
atrolysin C (Ht-d) and the endogenous venom peptide PyroGlu- 
Asn-Trp ( P E W ,  Ki with Ht-d is 3.5 pM) described recently 
(Zhang  et al., 1994;  PDB access code latl). According to an 85% 
sequence identity between both catalytic domains (Shannon et al., 
1989; Gomis-Ruth et al., 1994), the RMSD between the common 
backbone atoms of both enzymes  is only 0.5 8,. Similarly, as in the 
adamalysin/Pol 647 and adamalysin/Pol 656 complexes, the 
C-terminus of the tripeptide ligates the catalytic zinc ion, but does 
so in a rather monodentate manner, corresponding to an almost 90” 
rotation around the C-terminal Ca-C bond compared with the pres- 
ently described complexes (see Fig. 4). Therefore, in Ht-d/pENW, 
the second distant carboxylate oxygen atom points to Gly 109 0 
(the residue numbering is equivalent in both proteinases) of the 
upper rim (2.5 8, away) instead of to the oxygen atoms of the side 
chain of the general base Glu 143 0 ~ 1  and 062, as observed in the 
adamalysin complexes. The preceding side chain of the tryptophan 
inhibitor residue lies in the same plane in Ht-d/pENW as in 
adamalysin/Pol 647 and adamalysin/Pol 656 (see Fig. 4), but is 
slightly shifted toward the side chain of Thr 139. This corresponds 
to an anti-clockwise rotation of 42” around an axis perpendicular to 
the aromatic ring plane and centered on the C62 atom (super- 
imposable in both types of complexes) compared with our struc- 
tures. The preceding residues, asparagine in pENW, leucine of 
Fle in Pol 647/656, are nearly superimposable, with the side 
chains likewise pointing to the bulk solvent in both cases. The 
main differences arise in the N-termini of the inhibitor mol- 
ecules.  The carbonyl group of FleIl in Pol 647/656 (PyroGlu in 
pENW) points toward the molecular surface, making a hydrogen 
bond with Leu 170 N of the enzyme moiety in adamalysin I1 
complexes, whereas, in the Ht-d complex, this group points into 
the bulk solvent. The planes of the N-terminal rings are approx- 
imately edge to face (see Fig. 4). 
Comparison  with the complex of human neutrophil 
collagenase (HNC) and  SHBzlPp-Ala-Gly-NH2  and 
that of prostromelysin I enzyme moiety with its propeptide 
A close inspection of the structurally related matrix metallopro- 
teinases or vertebrate collagenases (MMPs) complexed with pep- 
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Fig. 3. Schematic  diagram  of  the  binding  of inhibitor Pol 656 to  the adama- 
lysin I1 active site. Hydrogen  bonds  are depicted as dashed lines. Similar 
orientation as in Figure  2A. 
Table 1. Zinc-coordination  geometry 
Bond  types 
Adam./Pol 647 Adam./Pol 656 
(A)  (A) 
Zn-His 142 Ne2 1.91 I .98 
Zn-His 146 Ne2 2.15  1.98 
Zn-His 152 Ne2 I .93 I .78 
Zn-Trp(Ctr)l2 01 2.63 2.83 
Zn-Trp(Ctr)lZ 0 2  2.73 2.76 
Glu143 OeI-Trp(Ctr)U 0 2  3.24 3.37 
Glu 143 0~2-Trp(Ctr)12 0 2  2.88 2.81 
Adam./Pol 647 Adam./Pol 656 
Angle  type (”) (”) 
His 142 Ne2-Zn-His 146 Ne2 
His 142 Ne2-Zn-His 152 Ne2 
His 146 Ne2-Zn-His 152 Ne2 
His 142 NrZ-Zn-Trp(Ctr)lZ 01 
His 146 NeZ-Zn-Trp(Ctr)lZ 01 
His 152 Nc2-Zn-Trp(Ctr)l2 01 
His 142 NeZ-Zn-Trp(Ctr)lZ 0 2  
His 146 NeZ-Zn-Trp(Ctr)IZ 0 2  
His 152 NeZ-Zn-Trp(Ctr)I:! 0 2  
98 
I l l  
1 0 0  
104 
133 
107 
74 
104 
I48 
102 
98 
108 
I I3 
I26 
IO8 
80 
I02 
154 
tidomimetic inhibitors, grouped together with adamalysins into the 
metzincin clan of MEPs, reveals some similarities. Particularly, the 
complex formed by HNC and the thiol-inhibitor 2-benzyl-3- 
mercaptopropanoyl-L-alanylglycinamide (SHBzlPp-Ala-Gly-NH2; 
Grams  et a!., 1995; PDB  access  code ljao) reveals, contrary to the 
currently described structures, a binding mode reminiscent of that 
of bound peptide substrates, mimicking the primed-site binding. 
HNC and adamalysin display a closely related active site confor- 
mation, especially on  the primed subsites. The backbones of both 
enzymes are nearly superimposable after least-squares fitting of 
just the three histidine residues comprised in the  long zinc-binding 
consensus sequence in the following segments: Lys  106-Thr I 13 
(“upper rim” of adamalysin 11) with Gly 158-Glu 165 of HNC 
(nomenclature according to Bode et al., 1994);  the  segment  after 
the (included) Met-turn and the S; -wall forming  segment residues 
Cys 164-Pro 172 (adamalysin 11) with Ala 21  3-Phe 221 of HNC; 
finally, the “bulged’ region forming the upper part of the S i -  
pocket (Val 136-Gly 154 in adamalysin, Leu 191-Ser 209 in 
HNC). This feature accounts for the similarity in binding. In the 
HNC/SHBzlPp-Ala-Gly-NH2-complex, the catalytic zinc ion is 
liganded by the thiol sulfur atom in a monodentate way (see 
Fig. 5) .  The vicinous Ca-atom at the entrance of the  Si-pocket is 
nearly superimposable with the I2 amide nitrogen atom in the 
adamalysin/Pol 647 and adamalysin/Pol 656 complexes. The at- 
tached, likewise bulky, hydrophobic side chain-a phenyl group in 
SHBzlPp-Ala-Gly-NH2, a (cyc1o)tryptophan in  Pol 647(Pol656)- 
points in both structure types  into the similarly shaped Si- 
pocket, the aromatic ring planes being parallel to each other. Both 
contiguous carbonyl oxygen atoms  lie very close together, pointing 
in the same direction to equivalent parts of the catalytic domains 
(see Fig. 5). 
The ligation of the adamalysin II inhibitors presently discussed 
is somewhat reminiscent of the anticationic binding of the inhib- 
itory propeptide in prostromelysin 1. A superimposition after least- 
squares fitting of both molecules (data not shown) reveals that the 
main difference between both inhibitory mechanisms arises from 
the fact that the propeptide around position Cys  75 does not fill up 
the hydrophobic Si-pocket. The side-chain Sy atom of Cys 75 
coordinates the catalytic zinc ion substituting the solvent molecule 
in the active structure, rotated in a manner that position PI  points 
toward the molecule and Pi to the bulk solvent. The preceding 
carbonyl group of Arg 74 in prostromelysin 1 is equivalent to FleI 1 
C and 0, pointing in the same direction. The  side chain of Arg 74 
(equivalent to the leucine side chain of FleII) is likewise directed 
away from the enzyme moiety, and the preceding Pro 73 closely re- 
sembles the furoyl moiety of FleII in direction and position of its 
carbonyl group and side chain. 
Fig. 2 (facing page). A: Stereo ribbon plot displaying the nonliganded adamalysin 11 structure in the traditional standard orien- 
tation with a hypothetic peptidic substrate binding to the active site cleft from left to right (N- to C-terminus). The regular 
secondary structure elements (helices in magenta, labels A-E strands in green. labels I-V), the active site residues liganding the 
catalytic zinc ion. the Met-turn, the sulfate anion, the structural calcium cation. and the two disulfide bridges are depicted and 
labeled. Figure created with MOLSCRIPT (Kraulis, 1991). Detail of the adamalysin I1 active site and inhibitor Pol 647 (R) and 
Pol 656 (C)  superimposed with the final (2F,h,, - Fca,c) electron density maps contoured at I C .  Same orientation as in Figure 2A. 
Figures created with TURBO-Frodo. 
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Fig. 4. Superimposition of adamalysin II/Pol647 (thick trace) and Ht-d/pENW (thin trace) after optimal least-squares fit of the protein 
parts as performed with TURBO-Frodo. The active site zinc ion and some adamalysin I1 residues are labeled. 
Implications for drug design  strategies for TACE: 
Pol 647 and Pol 656, putative TACE inhibitors? 
The catalytic domain of TACE is, with 258 residues (Black  et al., 
1997; Moss et  al.,  1997), somewhat larger than that of adamalysin 
11. A detailed structure-based sequence alignment of both MEPs 
displays several insertions and deletions (see Fig. 6), but verifies 
that the regular secondary structure elements, as well as segments 
involved in substrate recognition, are probably superimposable. 
Three larger insertions in the TACE structure (15 residues between 
helix B and strand 11, 9 residues between strand I11 and IV, and 21 
residues between strands IV and V, see Fig. 6) may allow some 
additional regular secondary structure elements in the upper do- 
main of TACE.  In particular, the region around segments Lys 106- 
Thr 113 around strand IV (adamalysin sequence; “upper rim” 
forming segments), Val 136-Asp 153 (around the active site he- 
lix D and forming the zinc-binding site), and Ile 165-Leu 170 
(Met-turn and specificity pocket base-forming segment) align rea- 
sonably well, in accordance with the similar specificity of adama- 
lysin 11-cleaving bonds of type Xxx-Leu-and TACE, whose 
target is a peptide bond between alanine and valine of membrane- 
bound tumor necrosis factor-a precursor. 
A detailed inspection of a modeled TACE active site (based on 
the adamalysin I1 structure, Fig. 7) reveals that none of the amino 
acid substitutions of the TACE model imposes any severe steric 
hindrance. Interestingly and characteristically, the residues embed- 
ded in the zinc-binding consensus sequence, the two key positions 
of the Met-turn (Met 166 and Pro 168), and three central residues 
of the upper rim forming segment (Lys 1 IO-Tyr 112) are abso- 
lutely conserved. Some differences do arise, however, resulting in 
a somewhat smaller Si-specificity pocket for TACE. A leucine at 
position 138 (valine in adamalysin 11) probably somewhat restricts 
Fig. 5. Superimposition of adamalysin II/Pol 647 (thick trace) and HNC/SHBzlPp-Ala-Gly-NH* (thin trace) after optimal least- 
squares fit of the protein parts as performed with TURBO-Frodo. The active site zinc ion and some adamalysin I1 residues are labeled. 
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TACE. RADPDPMKNTCKLLWADHRFYRYMGRGEESTTITWLIELIDRVDDIYRNTSWDNAGFK 
AdaII, - - - -  NLPQRYIELVWADRRVFMKYN-SDLNIIR~~EI~IINEFYRSL-------- 
I. I .... 1 . 1 1  I I I  * I l l  I I I I . .  
ssssssssshhhhhhhh hhhhhhhhhhhhhhhhhhhh 
I A 
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I " I  I * I  .I I I f * 11.. I f  .I I 
AdaII. - - - - - - -  NIRVSLTDLEIWSGQDFITIQSSSSNTLNSFGEWl7ERVLLTRKRHDNAQLLT 
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I1 B 1x1 
I * I 1.1 
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V 
TACE. YGKTILTK~F~+DXAECAPNECCGGK~ EY 
AdaII, H--SPINL AV?MAHELGHNLGMEH  ---KLXLRG---ASL  IHRPGL PG---RSY 
I I I  ..I *.. * I  
hhhk  hhhhhhhhhhhhh 
TACE. MFSNCSKQSIYKTIESKAQECFQER 
AdaII,  EFSDDSMGYYQKFLNQYKWILNK 
I I 1.1 I ..I . 
hhhhhhhhhhhhhhhh 
E 
Fig. 6. Structure-based sequence alignment of tumor necrosis factor a 
convertase (TACE) and adamalysin 11. Identical residues are vertically 
united by asterisks, similar ones by vertical strokes. The regular secondary 
structure elements of adamalysin I1 are denoted (h for helices, s for strands) 
and  labeled (helices A-D and strands I-V). Adamalysin segments used for 
modeling of the TACE active site are framed (106-1 13, 136-153, 16.5- 
170). 
the size of the hydrophobic Si-cavity. A superimposition of this 
TACE active site model with the coordinates of adamalysin/Pol 
656 reveals that this inhibitor would very probably interact as well 
with this mammalian cytokine-converting enzyme as with the snake 
venom MEP adamalysin. 
Conclusions 
The present work opens the door to the rational drug design 
against both venom adamalysins and the mammalian ADAMs 
including TACE and, thus, for regulation of the cascade of events 
produced by the TACE-mediated release of active TNFa in gen- 
eral inflammatory processes. In the case of envenomation, large 
amounts of cytokines  are liberated by MEPs and have been 
detected at the site of the injury, probably promoting local in- 
flammation and the production of MMPs, such as gelatinase B, 
putatively  further  involved  in  tissue  destruction  (Rosenberg 
et al., 1995). On the other hand, MEPs may trigger release of 
TNFa, starting a vicious circle leading to even more active TNFa 
released and eventually to matrix protein degradation and necro- 
sis (Moura da Silva et al., 1996). 
Crotalid and viperid venoms contain a large amount of one  or 
two tripeptides (PyroGlu-Asn-Trp and/or PyroGlu-Gln-Trp), which 
are  competitive but weak inhibitors of MEPs; this might constitute 
an advantage  for predators with respect to inhibitors that are l o -  
cated in a propeptide segment (as happens often in MMPs), and 
must be processed by other proteinases, because snakes need a 
fully active  enzyme as soon as the venom is diluted into the host 
circulation. Because snake MEPs belong to the broad clan of metz- 
incins, which include also MMPs (Bode et ai., 1993; Stocker 
et al., 1995), and are the root of the tree of mammalian ADAMs 
(Wolfsberg & White, 1996), structural characteristics of the in- 
hibitors Pol 647 and Pol 656 can be exploited for the design of 
compounds with powerful pharmacological effects in diseases 
characterized by overproduction of MEPs, or activation of TACE 
or other ADAMs. 
It has already been published (Gilardini-Montani et a!.. 1993) 
that the tripeptide Pol 509 (PyroGlu-Leu-Trp-OMe), very similar 
to those found in venoms, has important effects on human cells 
involved in immunological responses, increasing the efficiency of 
antigen presentation to T-lymphocytes. As regards Pol 647 itself, 
obtained by substituting a furan ring in place of the pyroglutamate 
group present in Pol 509, it has been shown that it inhibits hem- 
orrhagic activity and lethality of the venom of E. carinatus laekeyi 
injected in mice (Laing & Politi. 1995). antagonizes the processing 
of TNFa precursor and necrosis induced by two different MEPs 
(Moura  da Silva  et al.. 1996). and affects motility of selected cells 
(results not shown). It can therefore be concluded that even subtle 
substitutions in the structures of tripeptides selected by snakes 
might orientate toward selective pharmacological targets. Pol 656, 
which was found to be 10 times more effective than Pol 647 
against adamalysin 11, is considered a good starting point for the 
search of drugs to be specifically developed against human TACE. 
Fig. 7. Superimposition of  adamalysin II/Pol647 (protein moiety,  thick trace; inhibitor  thickest trace) and  the  adamalysin-based  TACE 
active site model (thin trace). The active site zinc ion and some adamalysin II  residues  are  labeled. 
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Materials  and  methods 
Enzyme preparation and crystallization 
Adamalysin I1 was purified and crystallized as described previ- 
ously (Kurecki et al., 1978; Gomis-Ruth et al., 1993). 
Inhibitor synthesis 
Inhibitors Pol 647 and Pol 656 (see Fig. 1) were synthesized fol- 
lowing the usual methods of chemical peptide synthesis (see Robeva 
et al., 1991), first coupling furan-2-carboxylic acid with leucine 
methylester and then, after hydrolysis, acidifing the esterified tryp- 
tophan (or its cyclic analogue, obtained by reacting tryptophan 
with formaldehyde in  the acidic medium), finally performing a last 
hydrolysis in order to free the carboxylic acid. 
Determination of the inhibitory properties 
of Pol 647 and Pol 656 
The substrate used in order to perform the inhibitory studies was 
2-aminobenzoyl-Ala-Gly-Leu-Ala-p-nitrobenzylamide (Bachem). It 
was prepared as a 1 mM solution in methanol. The reaction mix- 
ture was incubated at 30°C using a buffered solution (50 mM 
Tris.HCI, 100 mM NaCI, 10 mM CaC12) at pH 7.5, which con- 
Table 2. Detailed data collection statistics 
Resolution Completeness 
range 
(A) 
in shell 
Rmrrpea (a) W O  
tained 3 pL of substrate, 6 p g  of purified adamalysin 11, and 
different amounts of inhibitor previously dissolved in methanol. 
The enzymatic reaction was followed for several minutes by mea- 
suring the fluorescence of the cleaved substrate (excitation at 
320 nm; emission at 420 nm). 
Preparation of the enzyme-inhibitor complexes 
Inhibitors Pol 647 and Pol 656 were suspended (1 mg/mL) in 
harvesting buffer (see above), and native crystals were soaked in 
these suspensions at 4°C for 12 and 20 h, respectively. 
Data collection and crystallographic structure analysis 
X-ray diffraction data of inhibited adamalysin I1 were collected 
from a single crystal for each complex, rotated around two dif- 
ferent axes on a FAST television area detector diffractometer 
(Enraf Nonius, Delft) at 15 "C using Nickel-filtered CuK, radi- 
ation provided by a Rigaku Denki rotating anode X-ray gener- 
ator operated at 5.4 kW. Data up to 2.3 8, (adamalysin/Pol  647) 
and 2.5 8, (adamalysin/Pol 656) resolution, although not very 
complete in the high-resolution range, were processed online 
with the program MADNES (Messerschmidt & Pflugrath, 1987), 
corrected for absorption by means of ABSCOR (Messerschmidt 
~ 
Adamalysin II/Pol 647  (cell constants a = b = 73.55 A; c = 96.52 A) 
20.0-6.88 0.076 100.4 5.4 
6.88-5.01 0.079 99.5 7.4 
5.01-4.14 0.012 99.7 6.6 
4.14-3.60 0.087 99.7 7.1 
3.60-3.23 0.105 100.5 6.6 
3.23-2.96 0.135 94.9 5.2 
2.96-2.14 0.173 85.7 4.0 
2.74-2.51 0.229 14.5  3.0 
2.57-2.42 0.266 61.6 2.5 
2.42-2.30 0.325 48.2 2.0 
20.0-2.30 0.106 81.6 5.4 
Adamalysin II/Pnl 656  (cell constants a = b = 73.55 A; c = 96.67 A) 
20.0-7.40 0.103 98.5 4.0 
1.40-5.42 0.103 99.4 5.2 
5.42-4.48 0.094 99.5 5.2 
4.48-3.91 0.098 98.7 5.6 
3.91-3.51  0.1  10 100.8 6.0 
3.51-3.21 0.130 94.4 5.3 
3.21-2.98 0.169 82.4 4.1 
2.98-2.79 0.206 67.4 2.8 
2.79-2.63 0.249 56.0 2.7 
2.63-2.50 0.320 45.7 1.9 
20.0-2.50  0.120  78.9 4.4 
No. of No. of 
measurements reflections Multiplicity 
1,348 
2,313 
2,992 
3,632 
4,154 
3,924 
3.146 
2,597 
2,227 
1,486 
27,819 
923 
1,527 
1,940 
2,305 
2,678 
2,608 
2,153 
1,724 
1,520 
1,153 
18,531 
526 
818 
1,025 
1.200 
1,357 
1,402 
1,372 
1.276 
1,118 
924 
11,018 
406 
64 1 
80 1 
928 
1,059 
1,085 
1,023 
896 
192 
680 
8,311 
2.6 
2.8 
2.9 
3.0 
3.1 
2.8 
2.3 
2.0 
2.0 
1.6 
2.5 
2.3 
2.4 
2.4 
2.5 
2.5 
2.4 
2.1 
I .9 
1.9 
1.7 
2.2 
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Table 3. Final rejinement statistics 
Adamalysin  II/inhibitor  complex  Adam./Pol 647 Adam./Pol  656 
Resolution  range (A) 
Number of reflections 
used  in  refinement (>2cr) 
Non-hydrogen  protein  atoms 
Solvent  molecules 
Crystallographic  R-factora 
RMSD from target  values 
Bonds (A) 
Angles (") 
Bonded Bs (A2) 
7.0-2.6 
7,7 19 
1,616 
165 
0.191 
0.007 
1.23 
2.52 
7.0-2.8 
5,926 
1,616 
129 
0.194 
0.008 
I .30 
et a]., 1990), and loaded, scaled, and merged with PROTEIN 
(Steigemann, 1991) and programs of the  CCP4  suite (CCP4, 
1994). The data collection statistics are presented in Table 2. 
Because the data are reasonably complete (>60%) in the shells 
from 2.74 to 2.57 A (74.5%) and from 2.98 to 2.79 A (67.4%) 
for adamalysin in complex with Pol 647 and Pol 656, respec- 
tively, resolution cutoffs for refinement of 2.6 8, and 2.8 A were 
chosen. An initial 2.6 or 2.8 8, (2FObs - For,) electron density 
map was computed with the CCP4 package (CCP4, 1994) using 
sigmaa-weighted calculated phases of the refined nonliganded 
adamalysin I1 model (Gomis-Ruth et al., 1993). Models of the 
inhibitor molecules were built into this map using TURBO- 
Frodo version 5.0a (Bio-Graphics, Marseille) on a Silicon Graph- 
ics workstation. The complexes were then subjected to a reciprocal 
space least-squares refinement with energy constraints as imple- 
mented in X-PLCR v. 3.851 (Briinger, 1991) using bond and 
angle parameters derived from the Cambridge Structural Data- 
base (Engh & Huber, 1991). The refined models were fitted to 
the improved density and further refined until convergence. In 
the final steps of refinement, individual constrained temperature 
factors (for adamalysin/Pol  647) and an overall temperature fac- 
tor (for adamalysin/Pol 656) were refined. Most of the solvent 
molecules, the sulfate anion, and both metal ions observed in 
the native structure (Gomis-Ruth et al., 1993) were retained in 
the complex structures and some additional solvent molecules 
were introduced at stereochemically reasonable positions if the 
corresponding omit maps showed appropriate (2F,b,T - Fcorc) 
electron  density ( > l o )  and difference  density (>2o). The 
final crystallographic R-factors of these two new structures are 
0. i 9 1 (adamalysin/Pol 647) and 0.194 (adamalysin/Pol 656). 
For adamalysin/Pol  647, the RMSD of bonded temperature fac- 
tors is 2.52 A* (adamalysin/Pol 647). The final refinement sta- 
tistics are shown in Table 3. Coordinates will be deposited in 
the Brookhaven Protein Data Bank (PDB access codes 2aig and 
3aig). 
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